Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04802837 · ClinicalTrials.gov registry record · Phase 3
Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects
A Phase 3 study, sponsored by Summit Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2
- Enrollment target
NCT04802837: Clinical Trial Phase 3 study, sponsored by Summit Therapeutics.
NCT04802837 is a Phase 3 study that was terminated before completion, run by Summit Therapeutics. The registered enrollment target is 2 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04802837, a Phase 3 study, was terminated before completion, sponsored by Summit Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2 participants
- Enrollment target
Study Summary
Study to evaluate the safety of ridinilazole in adolescent subjects and how ridinilazole is metabolized.
Primary Outcome
Safety was assessed using CTCAE v4.
Interventions
- DRUG Vancomycin
- DRUG Ridinilazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-05-19 |
| Est. Completion | 2022-09-28 |
| Phase | Phase 3 |
Why NCT04802837 stopped before completion
NCT04802837 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Vancomycin is the first listed.
NCT04802837 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04802837 about?
NCT04802837 is a clinical study titled "Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects". Study to evaluate the safety of ridinilazole in adolescent subjects and how ridinilazole is metabolized.
What is the current status of trial NCT04802837?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2 participants. The study started on 2021-05-19. Estimated completion is 2022-09-28.
What interventions are being tested in trial NCT04802837?
The interventions under investigation include: Vancomycin (DRUG), Ridinilazole (DRUG).
Who is sponsoring clinical trial NCT04802837?
This trial is sponsored by Summit Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04802837's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI